Novo Nordisk Takes On Sanofi Over Insulin Pens

Law360, New York (July 17, 2007, 12:00 AM EDT) -- Denmark-based drug maker Novo Nordisk A/S has filed a suit against Sanofi-Aventis and its U.S. affiliate for allegedly infringing an injection device patent through the French pharmaceutical company's yet-to-be-launched insulin pen SoloStar.

Wasting no time in enforcing the rights to its invention, Novo Nordisk filed the suit on July 10, the same day that the U.S. Patent and Trademark Office issued the patent entitled “injection device.”

Novo Nordisk claims that Sanofi-Aventis' SoloStar, a prefilled disposable insulin pen, violates the patent. The Danish company is seeking an...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.